Praxis (NASDAQ: PRAX) accounting officer adds shares through employee stock purchase plan

Rhea-AI Filing Summary

Praxis Precision Medicines principal accounting officer Lauren Mastrocola reported an acquisition of company stock through an employee plan. On this Form 4, she acquired 127 shares of Praxis Precision Medicines, Inc. common stock at $167.943 per share. These shares were purchased under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). After this award, she directly holds a total of 13,572.656 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mastrocola Lauren

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	127	$167.943	$21K

Holdings After Transaction: Common Stock — 13,572.656 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 127 shares Acquisition price: $167.943 per share Post-transaction holdings: 13,572.656 shares

3 metrics

Shares acquired 127 shares Common stock grant/award acquisition on May 14, 2026

Acquisition price $167.943 per share Price for 127 acquired common shares

Post-transaction holdings 13,572.656 shares Total common shares directly held after the Form 4 transaction

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c), Grant, award, or other acquisition

4 terms

Employee Stock Purchase Plan financial

"These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt..."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(d) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mastrocola Lauren

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		127	A	$167.943	13,572.656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Praxis Precision Medicines (PRAX) report in this Form 4 for Lauren Mastrocola?

Praxis Precision Medicines reported that principal accounting officer Lauren Mastrocola acquired 127 shares of common stock. The shares were obtained through the company’s Employee Stock Purchase Plan and are classified as a grant or award acquisition, reflecting routine equity-based compensation rather than an open-market trade.

How many Praxis Precision Medicines (PRAX) shares does Lauren Mastrocola hold after this Form 4 transaction?

Following this transaction, Lauren Mastrocola directly holds 13,572.656 shares of Praxis Precision Medicines common stock. This total includes the newly acquired 127 shares reported on the Form 4 and represents her direct ownership position as of the transaction date disclosed in the filing.

At what price were the Praxis Precision Medicines (PRAX) shares acquired in this Form 4 filing?

The 127 Praxis Precision Medicines common shares were acquired at a price of $167.943 per share. This price is reported in the Form 4 and applies to the shares obtained under the Employee Stock Purchase Plan, which are treated as an exempt grant or award acquisition.

Was the Praxis Precision Medicines (PRAX) Form 4 transaction by Lauren Mastrocola an open-market purchase or a plan acquisition?

The transaction was a plan acquisition, not an open-market purchase. The footnote explains the 127 shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating routine, plan-based equity participation.

What SEC rules are cited in the Praxis Precision Medicines (PRAX) Form 4 footnote for this transaction?

The Form 4 footnote states that the shares were acquired in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c). These rules provide exemptions for certain insider transactions involving employee benefit or stock purchase plans, clarifying the regulatory treatment of this equity award acquisition.